Nipent (Pentostatin)

Pentostatin, the active ingredient in Nipent, is a purine analog antimetabolite presented as a sterile solution for intravenous use. It treats hairy cell leukemia in adult patients by targeting malignant lymphocytes.\n\nGNH India supplies Nipent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Pentostatin is employed in the management of hematologic malignancies, specifically targeting B‑cell disorders.\n\nHairy cell leukemia: induces remission by inhibiting adenosine deaminase in malignant lymphocytes, leading to selective cytotoxicity.

Pentostatin may cause a range of adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Fatigue or weakness\n- Low white blood cell count (neutropenia)\n- Mild fever or chills\n\nSerious or Rare Side Effects:\n- Severe infection due to profound immunosuppression\n- Hepatic toxicity (elevated transaminases)\n- Anaphylactic or severe hypersensitivity reactions

Pentostatin requires careful monitoring and specific safety measures before and during therapy.\n\nRenal function: assess baseline creatinine and adjust if impaired\nHepatic function: evaluate liver enzymes prior to initiation\nInfection risk: screen for active infections and vaccinate before treatment when possible\nConcurrent myelosuppressive agents: avoid or use with close hematologic monitoring\nPregnancy and lactation: contraindicated; discuss alternatives with the prescriber\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pentostatin can interact with other medicines, altering its safety or effectiveness.\n\nMajor Interactions (Avoid):\n- Concurrent use with other myelosuppressive chemotherapy agents (e.g., fludarabine)\n- Live vaccines administered during therapy\n\nModerate Interactions (Monitor Closely):\n- Allopurinol, which may increase pentostatin toxicity\n- Antifungal azoles that affect renal clearance